FDA Approves Zynyz® as First-Line Treatment for Advanced Anal Cancer in the U.S.
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr), the First and Only Approved First-Line Treatment for Advanced Anal Cancer in the U.S. Incyte Corporation (Nasdaq: INCY), a global biopharmaceutical company focused…
Merck Demonstrates Resilience with Continued Growth
Merck Delivers Resilient Growth Across All Divisions in Q1 2025, Advances Strategic Expansion with SpringWorks Acquisition Merck, the global science and technology powerhouse, began 2025 on strong footing, demonstrating solid…
Regeneron Wins Antitrust Suit Against Amgen Over PCSK9 Drug Access
Regeneron Triumphs in Landmark Antitrust Case Against Amgen Over PCSK9 Inhibitor Market Practices In a major legal victory that could have lasting implications for the biotechnology and pharmaceutical industries, Regeneron…
CSL Behring Named 2025 ISPE Facility of the Year Award Winner
CSL Behring’s Broadmeadows Plasma Facility Wins Prestigious 2025 ISPE Facility of the Year Award for Pharma 4.0 Innovation CSL Behring has earned global recognition for its trailblazing approach to pharmaceutical…
Gilead and Kite to Present Key CAR T and Cancer Data at 2025 ASCO and EHA
Gilead and Kite Set to Showcase Transformative Oncology Data at 2025 ASCO and EHA Conferences, Highlighting Advances in Breast Cancer, Multiple Myeloma, and Glioblastoma Gilead Sciences,and its Kite subsidiary are…
Merck’s Phase 3 KEYNOTE-B96 Trial Meets PFS Goal in Platinum-Resistant Ovarian Cancer
Merck’s KEYTRUDA-Based Regimen Achieves Major Milestone in Phase 3 KEYNOTE-B96 Trial for Platinum-Resistant Ovarian Cancer Merck & Co., Inc. (NYSE: MRK), operating as MSD outside the United States and Canada,…
GSK to Acquire Phase III-Ready Efimosfermin for Steatotic Liver Disease
GSK Acquires Phase III-Ready Efimosfermin for $1.2 Billion in Bid to Transform Steatotic Liver Disease Treatment GSK has announced a major strategic acquisition in the field of hepatology, entering into…
FDA Approves Merck’s WELIREG for Advanced PPGL in Patients 12 and Older
FDA Approves Merck’s WELIREG® (belzutifan) for Advanced Pheochromocytoma and Paraganglioma in Patients 12 Years and Older, Marking a New Era in Treatment of Rare Neuroendocrine Tumors Merck, known as MSD…
AbbVie and ADARx Pharmaceuticals Forge Collaboration and Licensing Deal to Advance Next-Gen siRNA Therapies Across Diverse Disease Areas
AbbVie and ADARx Partner to Advance Next-Generation siRNA Therapies Across Neuroscience, Immunology, and Oncology in Multibillion-Dollar Collaboration AbbVie, a global biopharmaceutical leader known for its portfolio of therapies in immunology,…
FDA Approves EMRELIS for Advanced NSCLC With High c-Met Expression
AbbVie Gains First Solid Tumor FDA Approval With EMRELIS™ for High c-Met Overexpressing Advanced NSCLC AbbVie has achieved a key milestone in its oncology pipeline with the announcement that the…
Novo Nordisk, Septerna Partner on Oral Obesity, Cardiometabolic Drugs
Novo Nordisk and Septerna Forge $2.2 Billion Global Alliance to Develop Oral Small Molecule Therapies for Obesity and Cardiometabolic Diseases In a significant expansion of its research and development pipeline,…
WHO Announces Members of Surgical Sub-Group for Caesarean Section Guidelines
WHO Establishes Expert Surgical Sub-Group to Develop Global Guidelines for Caesarean Section Practices Caesarean section, often referred to as C-section, has become the most common major abdominal surgery performed across…